Brokerages expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report sales of $1.42 billion for the current quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Alexion Pharmaceuticals' earnings, with the highest sales estimate coming in at $1.49 billion and the lowest estimate coming in at $1.34 billion. Alexion Pharmaceuticals reported sales of $1.26 billion in the same quarter last year, which suggests a positive year over year growth rate of 12.7%. The firm is scheduled to report its next quarterly earnings report on Wednesday, October 28th.
On average, analysts expect that Alexion Pharmaceuticals will report full-year sales of $5.76 billion for the current year, with estimates ranging from $5.58 billion to $5.88 billion. For the next fiscal year, analysts forecast that the business will post sales of $6.35 billion, with estimates ranging from $5.92 billion to $6.70 billion. Zacks' sales averages are a mean average based on a survey of research firms that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $3.11 EPS for the quarter, beating the Zacks' consensus estimate of $2.32 by $0.79. The company had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.27 billion. Alexion Pharmaceuticals had a net margin of 15.28% and a return on equity of 22.57%.
A number of equities research analysts have recently weighed in on ALXN shares. BidaskClub upgraded shares of Alexion Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, September 17th. William Blair restated a "hold" rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, October 7th. Raymond James cut their target price on shares of Alexion Pharmaceuticals from $156.00 to $151.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. TheStreet cut shares of Alexion Pharmaceuticals from a "b-" rating to a "c" rating in a research report on Thursday, July 30th. Finally, Stifel Nicolaus cut their target price on shares of Alexion Pharmaceuticals from $120.00 to $117.00 and set a "hold" rating for the company in a research report on Tuesday, September 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of "Buy" and a consensus price target of $140.81.
NASDAQ:ALXN opened at $121.76 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.28 and a current ratio of 4.79. The stock has a market capitalization of $26.69 billion, a P/E ratio of 32.56, a PEG ratio of 1.05 and a beta of 1.35. The company has a 50 day moving average price of $114.97 and a 200 day moving average price of $108.19. Alexion Pharmaceuticals has a fifty-two week low of $72.67 and a fifty-two week high of $128.57.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Evolution Wealth Advisors LLC boosted its stake in shares of Alexion Pharmaceuticals by 766.7% in the third quarter. Evolution Wealth Advisors LLC now owns 260 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 230 shares during the period. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Alexion Pharmaceuticals by 62.8% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 280 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 108 shares during the period. CWM LLC grew its position in Alexion Pharmaceuticals by 135.9% in the 3rd quarter. CWM LLC now owns 401 shares of the biopharmaceutical company's stock valued at $46,000 after buying an additional 231 shares in the last quarter. Whittier Trust Co. grew its position in Alexion Pharmaceuticals by 90.0% in the 2nd quarter. Whittier Trust Co. now owns 475 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 225 shares in the last quarter. Finally, Verus Capital Partners LLC grew its position in Alexion Pharmaceuticals by 560.0% in the 1st quarter. Verus Capital Partners LLC now owns 660 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 560 shares in the last quarter. Institutional investors own 90.12% of the company's stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Read More: Cash Flow Analysis in Stock Selection
Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Energy Stocks Analysts Love the Most
There are more than 450 energy companies traded on public markets. Given the sheer number of pipeline companies, power plant operators, oil and gas production companies and other energy stocks, it can be hard to identify which energy companies are going to outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 8,000 distinct recommendations for energy companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same energy stock.
This slide show lists the 15 energy companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Energy Stocks Analysts Love the Most".